Enliven Therapeutics (ELVN)

• Market cap: $3.85B
• 1 day: 1.85%
• 5 days: 1.51%
• 1 month: 6.31%
• 3 months: 30.85%
• 6 months: 103.97%
• Year to date: 247.17%
• 1 year: 179.24%
• 5 years: 150.23%
• 10 years: -10.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Employees: 61